Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Lumacaftor/ivacaftor (LUMA-IVA) therapy is prescribed to people with cystic fibrosis (pwCF) homozygous for the Phe508del-CFTR variant to restore CFTR protein function. There is, however, large inter-individual variability in treatment response. Here, we seek to identify clinical and/or genetic factors that may modulate the response to this CFTR mod...
Alternative Titles
Full title
Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8876860
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8876860
Other Identifiers
ISSN
2075-4426
E-ISSN
2075-4426
DOI
10.3390/jpm12020252
